Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The Сompany also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its prodcuts, include Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

Show more
Indianapolis, US
Size (employees)
41,975 (est)
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Report incorrect company information

Key People/Management at Eli Lilly

David Ricks

David Ricks

Chairman and Chief Executive Officer
Susan Mahony

Susan Mahony

Senior Vice President and President, Lilly Oncology
Jeffrey Simmons

Jeffrey Simmons

Senior Vice President and President
Alfonso Zulueta

Alfonso Zulueta

Senior Vice President and President, Lilly International
Stephen Fry

Stephen Fry

Senior Vice President, Human Resources and Diversity
Melissa Barnes

Melissa Barnes

Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Show more

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 141 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Toronto, CA
3650 Danforth Ave
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham, GB
Erl Wood Manor Sunninghill Road
Show all (196)
Report incorrect company information

Eli Lilly Financials and Metrics

Eli Lilly Financials

Eli Lilly's revenue was reported to be $21.22 b in FY, 2016 which is a 6.3% increase from the previous period.

Revenue (FY, 2016)

21.2 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

15.6 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

2.7 b

Market capitalization (25-Apr-2018)

85.4 b

Cash (31-Dec-2016)

4.6 b


89.1 b
Eli Lilly's current market capitalization is $85.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


23.1 b19.6 b20 b21.2 b

Revenue growth, %


Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b
USDFY, 2013FY, 2014FY, 2015FY, 2016


3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m


2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)
USDY, 2016


18.4 x


511.3 k


0.6 x


0.2 x

Financial Leverage

2.8 x
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
CoLucid Pharmaceuticals January 18, 2017$960 m
Novartis Animal Health April 22, 2014$5.40 b
Avid Radiopharmaceuticals November 08, 2010$800 m
Alnara Pharmaceuticals July 02, 2010$280 m
Imclone Systems October 06, 2008$6.50 b
Report incorrect company information

Eli Lilly News and Updates

Eli Lilly's Cyramza rallies back in liver cancer with biomarker win

After Eli Lilly’s Cyramza flopped a phase 3 liver cancer trial in 2014, the company went back to the drawing board to design a trial for a specific subpopulation. Nearly four years later, it’s back with a win.

BRIEF-Tasly Pharma's Unit Signs Licensing Agreement On Diabetes Medicine With Eli Lilly

* SAYS UNIT SIGNS LICENSING AGREEMENT ON DIABETES MEDICINE WITH ELI LILLY Source text in Chinese: https://bit.ly/2EfkbCp Further company coverage: (Reporting by Hong Kong newsroom)

Half-off sale at Eli Lilly as drug rebating climbs to 51% in 2017

Jockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year. That 51% average cut stemmed from 9.7% list-price hikes that sank to 6% after wheeling and dealing with payers.

Eli Lilly nabs another breast cancer approval for third-to-the-party Verzenio

It’s been just five months since Eli Lilly breast cancer drug Verzenio hit the market, but the product has racked up its third approval, broadening its group of eligible patients and putting it on more even footing with rivals from Pfizer and Novartis.

Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer

Eli Lilly has steered away from megadeals, and a big influx of cash from U.S. tax reform won’t change that. Darren Carroll, SVP of business development, thinks behemoth buys will get the biggest boost as companies bring overseas earnings home, but “those deals, frankly, we don’t believe are very hel…
Show more
Report incorrect company information